Company intelligence / Profile preview

PBD Biotech

Birmingham, United Kingdompbdbio.com ↗

Ownership: Private
Development stage: Phase 3

Overview

PBD Biotech has developed a proprietary, patented phage-based diagnostic technology called Actiphage that can rapidly detect the presence of viable mycobacteria—the causative agents of tuberculosis—in blood samples from both humans and animals. The test distinguishes between live infectious organisms and those that are nonviable or present due to vaccination, providing results within approximately eight hours[1][2][4].

Therapeutic areas: Infectious Diseases
Modalities: Device (diagnostic)Phage-based diagnostics technology
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Actiphage

Phase 3

Indications: Tuberculosis

Partnerships

Nottingham Technology Ventures

Beyond the preview

Go deeper on PBD Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBD Biotech.

Explore the full profile